Ivermectin: ‘Bogus' or ‘Miracle Drug?'
Newsweek|October 22, 2021
Separating science from politics is tough—especially when the public and politicians are looking over scientists’ shoulders
DAVID H. FREEDMAN
Ivermectin: ‘Bogus' or ‘Miracle Drug?'

DOWN BUT NOT OUT Based on the data so far, most scientists expect ivermectin to follow hydroxychloroquine into the dustbin of dubious medical claims. Nevertheless, there are still three large, randomized studies of the drug still ongoing, and some experts caution against awaiting those results before ruling it out.

ANDREW HILL KNOWS FIRSTHAND WHAT IT’S like to bring a breakthrough drug to fruition. The pharmacology researcher at the University of Liverpool in the U.K. helped develop antiviral medications for HIV. “You think about helping to save millions of lives,” he says. “It was a wonderful feeling.”

Last year Hill was also excited about ivermectin, a 40-year-old generic drug shown in early laboratory experiments to inhibit the reproduction of SARS-CoV-2, the virus that causes COVID-19. Since ivermectin was already being produced in industrial quantities as a treatment for parasites in people and animals, it could potentially provide a lifeline to thousands of COVID patients struggling for breath in emergency rooms around the world—but only if it proved effective in the clinic, not just in a petri dish.

Some of the early, promising studies were found to be flawed; one clinical trial was halted when the drug showed no benefit. Hill reported that the drug didn’t seem to be living up to its early promise.

This story is from the October 22, 2021 edition of Newsweek.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the October 22, 2021 edition of Newsweek.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM NEWSWEEKView All
John David Washington
Newsweek US

John David Washington

FOR JOHN DAVID WASHINGTON, BRINGING NETFLIX'S THE PIANO LESSON (November 22) from stage to screen was a family affair.

time-read
1 min  |
December 06-13, 2024
A Walk in the Parks
Newsweek US

A Walk in the Parks

Jim O'Heir shares his memories of the hit NBC mockumentary and its cast's hopes of a reunion

time-read
4 mins  |
December 06-13, 2024
Philomena Cunk
Newsweek US

Philomena Cunk

PHILOMENA CUNK IS JUST AS SURPRISED AS anyone else at her own popularity.

time-read
1 min  |
December 06-13, 2024
SOLVING THE PLASTIC PROBLEM
Newsweek US

SOLVING THE PLASTIC PROBLEM

PLASTIC WASTE IS HARMING ANIMALS AND OUR PLANET. CAN THE DAMAGE BE UNDONE?

time-read
10 mins  |
December 06-13, 2024
'I Was Struck by How Humbled and Insignificant I Felt'
Newsweek US

'I Was Struck by How Humbled and Insignificant I Felt'

An explorer says coming face-to-face in the wild with a grizzly and her cubs changed his perspective on life

time-read
4 mins  |
December 06-13, 2024
Has AI Turned On Health Care?
Newsweek US

Has AI Turned On Health Care?

Hospitals hoped artificial intelligence would lighten their staff's workload, but the same tech could be to blame as insurance firms increasingly deny Medicare Advantage claims

time-read
7 mins  |
December 06-13, 2024
The Next Phase of War
Newsweek US

The Next Phase of War

After thousands of elite soldiers from North Korea joined Vladimir Putin’s forces against Ukraine, how has this latest move affected the conflict?

time-read
6 mins  |
November 29, 2024
Saying No to Trump and Men
Newsweek US

Saying No to Trump and Men

The election has led some women to boycott relationships and sex

time-read
7 mins  |
November 29, 2024
My Fight for Equality and Justice
Newsweek US

My Fight for Equality and Justice

It will take more than just science to end AIDS. Inclusion, empathy and compassion are essential, too

time-read
3 mins  |
November 29, 2024
NEW WORLD ORDER
Newsweek US

NEW WORLD ORDER

HOW LEADERS ACROSS THE GLOBE ARE REACTING TO DONALD TRUMP'S REELECTION AS U.S. PRESIDENT

time-read
10+ mins  |
November 29, 2024